Ensysce Biosciences to Participate in the 37th Annual ROTH Conference
Watch Ensysce Biosciences' latest callEnsysce Biosciences (NASDAQ:ENSC) Q2 2026 Earnings Call · Replay · Aug 18Read the transcript of Ensysce Biosciences (NASDAQ:ENSC) Q2 2026 Earnings CallThe original release is unavailable here.
Ensysce Biosciences, Inc. on 6ix
Story so far
Earlier from Ensysce Biosciences
- Ensysce Biosciences CEO Dr. Lynn Kirkpatrick and Creighton University's Dr. Neel Pathak Discuss the Opioid Crisis and Next Generation Opioids
- Ensysce Biosciences Reports Continued Positive Progress in Groundbreaking Trial on PF614-MPAR, Comments on Current Landscape for Pain Treatment
- Ensysce Biosciences Announces Positive Interim Data for Breakthrough Therapy PF614-MPAR
- Ensysce Biosciences Regains Full Compliance with Nasdaq
- Ensysce Biosciences Announces Commercial Supplier for Breakthrough Overdose Protection Drug Product
Later from Ensysce Biosciences
- Ensysce Biosciences Reports Fourth Quarter and Full Year 2024 Financial Results
- Ensysce Biosciences Announces PAINWeek 2025 Symposium and Recent Expert Panel Discussion on The State of the Nation in Pain
- Ensysce Biosciences, Inc. Announces $1.1 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
- Ensysce Biosciences Announces Positive Data from Opioid Overdose Protection Study
- Ensysce Biosciences Receives U.S. Patent for Groundbreaking Treatment of Opioid Use Disorder
Follow Ensysce Biosciences into a list and get an email when it puts out news.
Follow Ensysce Biosciences